Literature DB >> 19020779

Impact of insulin resistance on the progression of chronic liver diseases.

Kosuke Kaji1, Hitoshi Yoshiji, Mitsuteru Kitade, Yasuhide Ikenaka, Ryuichi Noguchi, Junichi Yoshii, Koji Yanase, Tadashi Namisaki, Masaharu Yamazaki, Kei Moriya, Tatsuhiro Tsujimoto, Hideto Kawaratani, Takemi Akahane, Masahito Uemura, Hiroshi Fukui.   

Abstract

Recent studies have revealed a close relationship between insulin resistance (IR) and the progression of chronic liver diseases, although relatively little is known regarding the possible mechanisms involved. The aim of this study was to elucidate the impact of IR on the development of liver fibrosis and hepatocarcinogenesis using obese diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Liver fibrosis development and glutathione-S-transferase placental form (GST-P)-positive pre-neoplastic lesions were both markedly accelerated in OLETF rats, being induced by pig serum and diethylnitrosamine (DEN), respectively. In the fibrosis experiment, alpha-smooth muscle actin-positive activated hepatic stellate cells (HSCs) also significantly increased in OLETF rats along with augmentation of the hepatic collagen content and transforming growth factor-beta1. Our in vitro study showed that both glucose and insulin stimulated the proliferation of activated HSCs, and the combination treatment exerted an additive effect. In the DEN model, neovascularization, which plays a pivotal role in hepatocarcinogenesis, was up-regulated in OLETF rats almost in parallel with pre-neoplastic lesion development and a potent angiogenic factor, vascular endothelial growth factor. High glucose and insulin also significantly augmented the in vitro neovascularization via extracellular signal-regulated kinase 1/2 phosphorylation. Similar to the effect on the activated HSCs, co-existence of both factors exerted a more potent effect than either single factor. In conclusion, these results indicated that the IR status directly accelerated liver fibrosis development and hepatocarcinogenesis at least partly through the stimulation of activated HSC proliferation and hepatic neovascularization, respectively, in the rat.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020779

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  18 in total

1.  Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2.

Authors:  Jianguo Lin; Anping Chen
Journal:  Mol Cell Endocrinol       Date:  2010-12-30       Impact factor: 4.102

Review 2.  Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma.

Authors:  Asma Siddique; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

3.  Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.

Authors:  Tsuyoshi Mashitani; Ryuichi Noguchi; Yasushi Okura; Tadashi Namisaki; Akira Mitoro; Hitoshi Ishii; Toshiya Nakatani; Eiryo Kikuchi; Hiroto Moriyasu; Masami Matsumoto; Shinya Sato; Tatsuichi An; Hiroshi Morita; Sigeyuki Aizawa; Yasunori Tokuoka; Masatoshi Ishikawa; Yoshinobu Matsumura; Hiromasa Ohira; Atsuko Kogure; Kazuhiro Noguchi; Hitoshi Yoshiji
Journal:  Biomed Rep       Date:  2016-01-07

4.  Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Kosuke Kaji; Yasuhide Ikenaka; Yusaku Shirai; Tadashi Namisaki; Mitsuteru Kitade; Tatsuhiro Tsujimoto; Hideto Kawaratani; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2009-11-26       Impact factor: 7.527

5.  Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Yosuke Aihara; Akitoshi Douhara; Hideto Kawaratani; Norihisa Nishimura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2013-11-07       Impact factor: 7.527

6.  Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis.

Authors:  Mitsuteru Kitade; Hitoshi Yoshiji; Ryuichi Noguchi; Yasuhide Ikenaka; Kosuke Kaji; Yusaku Shirai; Masaharu Yamazaki; Masahito Uemura; Junichi Yamao; Masao Fujimoto; Akira Mitoro; Masahisa Toyohara; Masayoshi Sawai; Motoyuki Yoshida; Chie Morioka; Tatsuhiro Tsujimoto; Hideto Kawaratani; Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2009-11-07       Impact factor: 5.742

7.  Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.

Authors:  Norihisa Nishimura; Mitsuteru Kitade; Ryuichi Noguchi; Tadashi Namisaki; Kei Moriya; Kosuke Takeda; Yasushi Okura; Yosuke Aihara; Akitoshi Douhara; Hideto Kawaratani; Kiyoshi Asada; Hitoshi Yoshiji
Journal:  J Gastroenterol       Date:  2016-03-29       Impact factor: 7.527

8.  Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimens.

Authors:  Masahiro Sakata; Akihiko Kawahara; Takumi Kawaguchi; Jun Akiba; Tomoki Taira; Eitaro Taniguchi; Mitsuhiko Abe; Hironori Koga; Masayoshi Kage; Michio Sata
Journal:  J Gastroenterol       Date:  2012-07-12       Impact factor: 7.527

9.  Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone.

Authors:  Shang-Yu Chai; Xiao-Yu Pan; Ke-Xiu Song; Yue-Ye Huang; Fei Li; Xiao-Yun Cheng; Shen Qu
Journal:  Lipids Health Dis       Date:  2014-01-07       Impact factor: 3.876

10.  Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease.

Authors:  Motoi Hashiba; Masafumi Ono; Hideyuki Hyogo; Yukio Ikeda; Kosei Masuda; Reiko Yoshioka; Yoichi Ishikawa; Yuri Nagata; Kensuke Munekage; Tsunehiro Ochi; Akira Hirose; Yasuko Nozaki-Fujimura; Shuhei Noguchi; Nobuto Okamoto; Kazuaki Chayama; Narufumi Suganuma; Toshiji Saibara
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.